Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Short-term safety of thoracoscopic talc pleurodesis for recurrent primary spontaneous pneumothorax: a prospective European multicentre study

P-O. Bridevaux, J-M. Tschopp, G. Cardillo, C-H. Marquette, M. Noppen, P. Astoul, P. Driesen, C.T. Bolliger, M.E. Froudarakis, J.P. Janssen
European Respiratory Journal 2011 38: 770-773; DOI: 10.1183/09031936.00189710
P-O. Bridevaux
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pierre-olivier.bridevaux@hcuge.ch
J-M. Tschopp
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Cardillo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C-H. Marquette
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Noppen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Astoul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Driesen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C.T. Bolliger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.E. Froudarakis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.P. Janssen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The safety of talc pleurodesis is under dispute following reports of talc-induced acute respiratory distress syndrome (ARDS) and death. We investigated the safety of large-particle talc for thoracoscopic pleurodesis to prevent recurrence of primary spontaneous pneumothorax (PSP).

418 patients with recurrent PSP were enrolled between 2002 and 2008 in nine centres in Europe and South Africa. The main exclusion criteria were infection, heart disease and coagulation disorders. Serious adverse events (ARDS, death or other) were recorded up to 30 days after the procedure. Oxygen saturation, supplemental oxygen use and temperature were recorded daily at baseline and after thoracoscopic pleurodesis (2 g graded talc).

During the 30-day observation period following talc poudrage, no ARDS (95% CI 0.0–0.9%), intensive care unit admission or death were recorded. Seven patients presented with minor complications (1.7%, 95% CI 0.7–3.4%). After pleurodesis, mean body temperature increased by 0.41°C (95% CI 0.33–0.48°C; p<0.001) at day 1 and returned to baseline value at day 5. Pleural drains were removed after day 4 in 80% of patients.

Serious adverse events, including ARDS or death, did not occur in this large, multicentre cohort. Thoracoscopic talc poudrage using larger particle talc to prevent recurrence of PSPS can be considered safe.

  • Pleural disease
  • pneumothorax
  • talc pleurodesis
  • thoracoscopy

Talc powder is the most inexpensive and efficient agent for pleurodesis, as shown in human [1–3] and animal studies [4]. In a prospective cohort study, Janssen et al. [5] recently demonstrated that thoracoscopic large-particle talc poudrage is safe in the treatment of malignant pleural effusions. Apart from treating malignant pleural effusions, graded talc has been extensively and safely used in Europe for >70 yrs for pleurodesis in recurrent spontaneous pneumothorax and has been shown to be well tolerated without long-term sequellae [6–9].

However, there is continued concern about the safety of talc pleurodesis for this indication following US reports of acute respiratory distress syndrome (ARDS) after talc application [10–13]. However, the incidence of ARDS after talc poudrage in primary spontaneous pneumothorax (PSP) is low. In a review of the literature from 1958 to 2001, Sahn [14] found reports of one case (0.15%) of respiratory failure following talc pleurodesis in 659 patients. Possible explanations for the occurrence of ARDS might be the dose of talc used [15, 16], the size of talc particles [17] as preparations vary markedly form one supplier to the other [18], or the form of talc administered (slurry talc versus poudrage) [10, 19]. These possible causes were postulated after occurrence of ARDS in patients with malignant pleural effusion and not pneumothorax.

The aim of this study was to assess the safety of large-particle talc applied in a standardised dose as poudrage under thoracoscopy in patients with recurrent PSP.

METHODS

Patients

Patients were prospectively enrolled between 2002 and 2008. Inclusion criterion was recurrent spontaneous pneumothorax for which the physician considered talc pleurodesis indicated. Patients with active pulmonary infection, unstable respiratory condition, coagulation disorders, bilateral pneumothorax or parenchymal lung disease, prior ipsilateral thoracic surgery or pleurodesis, or pregnancy were excluded. The study was approved by the Ethics committee of each participating hospital. Informed consent was obtained according to local protocols.

Thoracoscopic procedure

Thoracoscopy was performed under general or local anaesthesia by experienced pulmonologists according to current practice in Europe [20]. One or two entry ports were used to insert the videothoracoscope and the pneumatic atomiser. 2 g of graded talc (Steritalc®; Novatech, La Ciotat, France) were gently insufflated under visual control over the entire pleural surface [21]. Graded talc is characterised by the particle size, which has to be >10 μm and should contain only a small percentage of smaller particles. Thus, particles with a diameter of 6 μm have little or no ability to cross pleural stomata. The median particle size of Steritalc® is 31.5 μm, which is larger than talc manufactured in the USA [22].

At the end of the procedure a standard chest tube (20 to 28 French) was inserted for drainage of air and fluid. Anti-emetics and analgesics were administered according to the patient’s needs.

During the following 5 days, vital signs, temperature, use of supplemental oxygen and all medical and surgical complications were recorded. If necessary, additional chest radiographs were ordered. Drain removal day was left at the discretion of performing physicians.

Statistical analyses

Our primary end-point was ARDS during the first 30 days after the procedure. Based on published literature, we estimated the risk of ARDS to be <1%. We used exact confidence interval according to the method of Clopper and Pearson [23]. After an interim analysis, patient inclusion was stopped after 418 cases because no case of ARDS was identified. Comparisons of proportion of patients on supplemental oxygen and oxygen flow were performed using multilevel logistic and linear regression accounting for repeated measure. All analyses were performed with Stata 10 (StatCorp LP, College Station, TX, USA).

RESULTS

Table 1 shows the characteristics of the 418 included patients. Most of them were young (mean±sd 30.5±12.7 yrs) males (72.7%). For 61.1% of the thoracoscopies, two entry ports were used. Among the nine centres in Europe and South Africa participating in the study, two centres used exclusively two ports (Rome, Italy and Brussels, Belgium).

View this table:
  • View inline
  • View popup
Table 1– Patient characteristics

During the study period, no patients experienced ARDS or intensive care unit admission (95% CI 0.0–0.9%) (table 2).

View this table:
  • View inline
  • View popup
Table 2– Post-pleurodesis complications at 30 days

Supplemental oxygen was provided to most patients at baseline. By day 5, only six (0.01%) patients were still on oxygen (fig. 1). Mean oxygen flow decreased from 1.9 L·min−1 at baseline to 0.5 L·min−1 on day 5.

Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

Supplemental post-pleurodesis oxygen use from baseline to day 5. **: p<0.01 for all comparisons versus day 0, using multilevel regression accounting for repeated measures.

We observed a significant rise in temperature from baseline to day 4 and a return to baseline value on day 5. The mean temperature rose maximally by 0.41°C (95% CI 0.33–0.49°C) on day 1 and by 0.37°C (95% CI 0.29–0.44°C) on day 2 compared to baseline. On day 1, the temperature exceeded 37.9°C in 83 (21.2%) patients. Temperature changes are shown in figure 2, with box plots representing extreme changes in temperature.

Figure 2–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2–

Temperature change from baseline to day 5. Box plots represent median values and circles represent extreme values. #: p=0.708. **: p<0.01.

We recorded seven (1.7%, 95% CI 0.7–3.4%) non-ARDS comfplications (table 2). The most frequent complication was pulmonary infections requiring antibiotics (n=3). We also observed four cases of pleurodesis failure requiring surgical procedure. These four (<1%) patients were aged 20–84 yrs and had persistent leaks for >2 days. In one case bulla had to be surgically resected.

Drains were removed on day 4 or before day 4 following thoracoscopy in 80% of patients. In two patients, drains were removed on days 7 and 8, respectively (fig. 3).

Figure 3–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3–

Drain removal day. Data on drain removal were available for 264 patients. For two patients drains were removed on day 7 and 8, respectively.

DISCUSSION

Our study confirms the safety of thoracoscopic pleurodesis with graded talc for the treatment of recurrent PSP. No ARDS, intensive care unit admission or death were observed in our cohort of 418 patients. The most frequent adverse event was an increase in temperature, which was maximal on day 1. This result is in line with a previous study which documented the systemic inflammatory response induced by talc [24]. Supplemental oxygen was provided for a short period of time after talc pleurodesis. This suggests that talc-induced systemic inflammation is limited in severity and duration. Complications were pulmonary infections in <1% of procedures.

The absence of ARDS found in our prospective study supports the safety of graded talc use for pleurodesis in recurrent PSP, as has been previously reported in large retrospective studies [3, 20, 25].

Talc pleurodesis has been shown to be efficacious and safe with a success rate of 95% in PSP in large series [6–9, 25–27]. However, concerns about the safety of talc for pleurodesis were based on a small number of retrospective anecdotal reports of acute respiratory failure in patients with malignant pleural effusion [11–13]. In these reports, non-graded talc was used, which has been described to cross the visceral pleura and cause systemic inflammation, ARDS and even some deaths [12, 19]. Moreover, a recent study from North America using a higher dosage of talc (6 g) of unknown calibration raised concern about respiratory deterioration after thoracoscopic talc poudrage, even if the used talc was the only one approved by the US Food and Drug Administration [13]. Recent studies using graded talc with large particle size failed to observe ARDS cases [3, 7, 28]. In addition, in humans, systemic side-effects of talc appear to be related to overdoses of talc or uncalibrated talc with small particles [17].

In addition, acute respiratory failure can occur after re-expansion of the lung in the treatment of pneumothorax due to re-expansion oedema without pleurodesis, as has been reported recently [29].

Lack of power of our study to demonstrate an increased risk of ARDS might be discussed. However, our study is large enough to estimate this risk at <1%, which is clinically meaningful in regard of the risk of associated pneumothorax recurrence if left without pleurodesis.

In summary, our prospective study confirms, on a large scale, the short-term safety of talc pleurodesis in the treatment of patients with recurrent spontaneous pneumothorax.

Acknowledgments

The author’s affiliations are as follows. P-O. Bridevaux: Division of Pulmonary Medicine, University Hospitals of Geneva, Geneva, Swtizerland; J-M. Tschopp: Centre Valaisan de Pneumologie, Réseau Santé Valais, Crans Montana, Switzerland; G. Cardillo: Unit of Thoracic Surgery, Carlo Forlanini Hospital, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy; C-H. Marquette: Service de Pneumologie, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice, Nice, France; M. Noppen: Interventional Endoscopy Clinic and Respiratory Division, University Hospital Brussels, Brussels, Belgium; P. Astoul: Dept of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, North Hospital, University of the Mediterranean, Marseille, France; P. Driesen: Dept of Pneumology, Algemeen Ziekenhuis, Turnhout, Belgium; C.T. Bolliger: Lung Unit, Tygerberg Academic Hospital, Cape Town, South Africa; M.E. Froudarakis: Division of Pneumonology, Medical School of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece; J.P. Janssen: Dept of Pulmonary Diseases, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands.

We are indebted to the physicians who contributed to the data collection and the Centre de Recherche Clinique of the University of Geneva (Geneva, Switzerland) for statistical advice, especially D. Courvoisier.

The study protocol was designed by J-M. Tschopp, C-H. Marquette, M. Noppen, P. Astoul, P. Driesen, M.E. Froudarakis and J.P. Janssen. All authors contributed cases. J.P. Janssen co-ordinated the study and collected the data. The spread sheet for data collection was developed by J-M. Tschopp. P-O. Bridevaux performed the statistical analysis, with external consultation. P-O. Bridevaux and J-M. Tschopp drafted the manuscript, which was contributed to by all authors. All authors have seen and approved the final version.

Footnotes

  • Earn CME accreditation by answering questions about this article. You will find these at the back of the printed copy of this issue or online at www.erj.ersjournals.com/misc/cmeinfo.xhtml

  • Support Statement

    This study was received financial supp`ort from the Lancardis Foundation (Martigny, Switzerland).

  • Statement of Interest

    None declared.

  • Received December 9, 2010.
  • Accepted January 30, 2011.
  • ©ERS 2011

REFERENCES

  1. ↵
    1. Viallat JR,
    2. Rey F,
    3. Astoul P,
    4. et al
    . Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest 1996; 110: 1387–1393.
    OpenUrlCrossRefPubMedWeb of Science
    1. Berger R
    . Pleurodesis for spontaneous pneumothorax. Will the procedure of choice please stand up? Chest 1994; 106: 992–994.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Cardillo G,
    2. Carleo F,
    3. Giunti R,
    4. et al
    . Videothoracoscopic talc poudrage in primary spontaneous pneumothorax: a single-institution experience in 861 cases. J Thoracic Cardiovasc Surg 2006; 131: 322–328.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Fraticelli A,
    2. Robaglia-Schlupp A,
    3. Riera H,
    4. et al
    . Distribution of calibrated talc after intrapleural administration: an experimental study in rats. Chest 2002; 122: 1737–1741.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Janssen JP,
    2. Collier G,
    3. Astoul P,
    4. et al
    . Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007; 369: 1535–1539.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Lange P,
    2. Mortensen J,
    3. Groth S
    . Lung function 22–35 years after treatment of idiopathic spontaneous pneumothorax with talc poudrage or simple drainage. Thorax 1988; 43: 559–561.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Gyorik S,
    2. Erni S,
    3. Studler U,
    4. et al
    . Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax. Eur Respir J 2007; 29: 757–760.
    OpenUrlAbstract/FREE Full Text
    1. El Khawand C,
    2. Marchandise FX,
    3. Mayne A,
    4. et al
    . Pneumothorax spontani [Spontaneous pneumothorax. Results of pleural talc therapy using thoracoscopy]. Rev Mal Respir 1995; 12: 275–281.
    OpenUrlPubMedWeb of Science
  7. ↵
    1. Almind M,
    2. Lange P,
    3. Viskum K
    . Spontaneous pneumothorax: comparison of simple drainage, talc pleurodesis, and tetracycline pleurodesis. Thorax 1989; 44: 627–630.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Kennedy L,
    2. Harley RA,
    3. Sahn SA,
    4. et al
    . Talc slurry pleurodesis. Pleural fluid and histologic analysis. Chest 1995; 107: 1707–1712.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Campos JR,
    2. Werebe EC,
    3. Vargas FS,
    4. et al
    . Respiratory failure due to insufflated talc. Lancet 1997; 349: 251–252.
    OpenUrlPubMedWeb of Science
  10. ↵
    1. Rehse DH,
    2. Aye RW,
    3. Florence MG
    . Respiratory failure following talc pleurodesis. Am J Surg 1999; 177: 437–440.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Gonzalez AV,
    2. Bezwada V,
    3. Beamis JF Jr.,
    4. et al
    . Lung injury following thoracoscopic talc insufflation: experience of a single north American center. Chest 2010; 137: 1375–1381.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Sahn SA
    . Talc should be used for pleurodesis. Am J Respir Crit Care Med 2000; 162: 2023–2024.
    OpenUrlPubMedWeb of Science
  13. ↵
    1. Aelony Y
    . Talc pleurodesis. Talc slurry vs talc poudrage. Chest 1995; 108: 289.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Montes JF,
    2. Ferrer J,
    3. Villarino MA,
    4. et al
    . Influence of talc dose on extrapleural talc dissemination after talc pleurodesis. Am J Respir Crit Care Med 2003; 168: 348–355.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Maskell NA,
    2. Lee YC,
    3. Gleeson FV,
    4. et al
    . Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170: 377–382.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Ferrer J,
    2. Montes JF,
    3. Villarino MA,
    4. et al
    . Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest 2002; 122: 1018–1027.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Rinaldo JE,
    2. Owens GR,
    3. Rogers RM
    . Adult respiratory distress syndrome following intrapleural instillation of talc. J Thorac Cardiovasc Surg 1983; 85: 523–526.
    OpenUrlPubMedWeb of Science
  18. ↵
    1. Boutin C,
    2. Viallat J,
    3. Aelony Y
    , eds. Practical Thoracoscopy. Berlin, Sringer-Verlag, 1991.
  19. ↵
    1. Tschopp JM,
    2. Boutin C,
    3. Astoul P,
    4. et al
    . Talcage by medical thoracoscopy for primary spontaneous pneumothorax is more cost-effective than drainage: a randomised study. Eur Respir J 2002; 20: 1003–1009.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Navarro Jiménez C,
    2. Gómez Izquierdo L,
    3. Sánchez Gutiérrez C,
    4. et al
    . Analisis morfometricoy mineralogico de 14 muestras de talco usado para pleurodesis en distintos paises de Europa y America [Morphometric and mineralogical analysis of 14 samples of talc used for pleurodesis in several European and American countries]. Neumosur 2005; 17: 197–202.
    OpenUrl
  21. ↵
    1. Clopper C,
    2. Pearson ES
    . The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404–413.
    OpenUrlFREE Full Text
  22. ↵
    1. Froudarakis ME,
    2. Klimathianaki M,
    3. Pougounias M
    . Systemic inflammatory reaction after thoracoscopic talc poudrage. Chest 2006; 129: 356–361.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Weissberg D,
    2. Ben-Zeev I
    . Talc pleurodesis. Experience with 360 patients. J Thorac Cardiovasc Surg 1993; 106: 689–695.
    OpenUrlPubMedWeb of Science
    1. Kennedy L,
    2. Sahn SA
    . Talc pleurodesis for the treatment of pneumothorax and pleural effusion. Chest 1994; 106: 1215–1222.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Rodriguez-Panadero F,
    2. Antony VB
    . Pleurodesis: state of the art. Eur Respir J 1997; 10: 1648–1654.
    OpenUrlAbstract
  25. ↵
    1. Tschopp JM,
    2. Rami-Porta R,
    3. Noppen M,
    4. et al
    . Management of spontaneous pneumothorax: state of the art. Eur Respir J 2006; 28: 637–650.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Schmidt-Horlohe N,
    2. Rudig L,
    3. Azvedo CT,
    4. et al
    . Fulminant unilateral pulmonary edema after insertion of a chest tube: a complication after a primary spontaneous pneumothorax. Dtsch Arztebl Int 2008; 105: 878–881.
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 38 Issue 4 Table of Contents
European Respiratory Journal: 38 (4)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Short-term safety of thoracoscopic talc pleurodesis for recurrent primary spontaneous pneumothorax: a prospective European multicentre study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Short-term safety of thoracoscopic talc pleurodesis for recurrent primary spontaneous pneumothorax: a prospective European multicentre study
P-O. Bridevaux, J-M. Tschopp, G. Cardillo, C-H. Marquette, M. Noppen, P. Astoul, P. Driesen, C.T. Bolliger, M.E. Froudarakis, J.P. Janssen
European Respiratory Journal Oct 2011, 38 (4) 770-773; DOI: 10.1183/09031936.00189710

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Short-term safety of thoracoscopic talc pleurodesis for recurrent primary spontaneous pneumothorax: a prospective European multicentre study
P-O. Bridevaux, J-M. Tschopp, G. Cardillo, C-H. Marquette, M. Noppen, P. Astoul, P. Driesen, C.T. Bolliger, M.E. Froudarakis, J.P. Janssen
European Respiratory Journal Oct 2011, 38 (4) 770-773; DOI: 10.1183/09031936.00189710
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory clinical practice
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Article

  • Lung volumes and survival in chronic lung allograft dysfunction
  • EBUS-guided cryobiopsies in peripheral pulmonary lesions
  • Safety of formoterol in asthma clinical trials
Show more Original Article

Clinical Practice

  • Transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions
  • clinical practice
  • clinical practice
Show more Clinical Practice

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society